Shares of NuScale Power plunged 9% to $9.30 Thursday morning after UBS downgraded the small modular reactor developer from Neutral to Sell and slashed its price target from $10 to $6 — implying roughly 40% further downside from the prior close . The broader market rose, isolating NuScale as the clear underperformer and raising hard questions about whether the company's technology can reach customers before its money runs out.

  • Five-Plus Years to Build Means Revenue Stays a Mirage

UBS said competitors are moving toward construction while NuScale faces an estimated five-plus-year build timeline that presents meaningful challenges.

The bank now assumes only one project begins construction in 2028.

Even NuScale's Romania deal has faced several delays, with completion estimates already pushed out to 2034. For shareholders, every year of delay is another year of zero reactor revenue and continued dilution.

  • $700 Million in Cash Burn With Almost No Revenue Coming In

UBS forecasts approximately $700 million of cumulative cash burn from 2026 through 2028.

NuScale reported revenue of only $75,000 for Q2, down 99% from $8 million a year earlier — a collapse driven by the end of a Romanian engineering contract with nothing to replace it. The company exited Q2 with $1.9 billion in cash and no debt , but it has already launched a $750 million at-the-market stock offering program , meaning management is selling new shares into the market to fund operations — diluting existing investors' stakes.

  • No Binding Contracts, No Guaranteed Buyers

NuScale's partner ENTRA1 Energy is positioned for large-scale deployments and behind-the-meter projects for AI data centers, yet the absence of binding power purchase agreements matters more for how investors think about the timing of those hoped-for deployments.

NuScale's CFO recently guided investors to expect a power purchase agreement by the end of 2026 — a potential catalyst, but one that has been promised before.

  • Wall Street Is Split, but the Math Is Harsh

UBS projects revenue will rise from $185 million in 2028 to $924 million in 2030 , but earnings remain negative through 2030 . At the current stock price, UBS estimates the market implies $124 million of 2028 EBITDA — a measure of operating cash flow — compared to its own $29 million forecast. That gap suggests the stock still prices in a far rosier scenario than UBS believes is realistic, even after today's selloff.